Clinical evidence reveals a sobering reality: 60–70% of weight lost during GLP-1 therapy is regained within one year of medication discontinuation. This substantial weight rebound underscores a critical gap in current obesity treatment paradigms. While GLP-1 receptor agonists effectively suppress appetite and promote weight loss during active treatment, their discontinuation exposes the absence of sustained behavioral and lifestyle modifications. This finding challenges the notion that pharmacotherapy alone can achieve durable obesity management. The data compellingly demonstrates that obesity treatment must incorporate sustained multimodal intervention—combining medication with ongoing behavioral support, nutritional counseling, and systemic healthcare coordination. Without addressing the underlying drivers of weight gain and lifestyle patterns, even successful pharmacological interventions remain incomplete solutions.
Was this article helpful?
